(23 October 2025, Hong Kong) HKSH Medical Group (HKSH) is proud to announce the world’s first clinical study on stereotactic total ablative radiotherapy (STAR) with an MR-guided linear accelerator (MR-LINAC) for oligometastatic prostate cancer (OMPC). This study involved patients with advanced metastatic prostate cancer, utilising real-time motion tracking and precise image-guidance technology to target multiple tumour sites simultaneously. Participants underwent five sessions of “hypofractionation” radiotherapy, achieving outstanding results: a 100% three-year survival rate, over 95% achieving sustained disease control, and only mild side effects reported. As the first clinical study of its kind worldwide, this breakthrough provides new treatment options for advanced prostate cancer patients, reducing the burden and inconvenience of therapy while significantly improving quality of life. The findings were published in the July 2025 issue of the academic journal Frontiers in Oncology*.

Please click here [1] for more details.